New drug trial targets 'Undruggable' cancer mutation
NCT ID NCT07170293
Summary
This study is testing an experimental drug called tunlametinib for people with advanced solid cancers that have stopped responding to other treatments and have a specific genetic change called an NRAS mutation. The main goal is to see if the drug can shrink tumors and control the cancer. Researchers will also closely monitor for any side effects in the 15 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical Unversity Second Hospital
RECRUITINGTianjin, Tianjin Municipality, 300211, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.